Last updated: February 25, 2026
What is the Product and Its Market Position?
NDC 35573-0443 is marketed as a biologic therapeutic, primarily used to treat autoimmune disorders such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Its trade name, formulation details, and patent status are essential for analyzing its market dynamics.
Product Details:
- Manufacturer: Pfizer Inc.
- Active Ingredient: Infliximab (various biosimilar formulations possibly under development)
- Formulation: Intravenous infusion
- Indications: Rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis
Market Position:
- One of the earliest infliximab products launched in 1998.
- Competes in a market with biosimilar infliximab products since 2016.
- Holds significant brand recognition with established payer coverage and patient adherence rates.
Market Size and Trends
Current Market Data (2022-2023):
| Metric |
Value |
Source |
| Global biologic autoimmune drug market |
$45.8 billion |
EvaluatePharma [1] |
| Infliximab (major biologic segment) |
$7.9 billion |
IQVIA [2] |
| Market growth rate (CAGR 2022-2027) |
6.2% |
MarketsandMarkets [3] |
| Estimated infliximab revenue in 2023 |
$8.4 billion |
IQVIA [2] |
Key Market Factors:
- Increasing prevalence of autoimmune diseases.
- Expanding biosimilar approvals reducing prices.
- Growing access in emerging markets.
- Patent expiration for Smith & Nephew’s original infliximab patent in 2018 opened the market for biosimilars.
Key Competitors:
- Roche (Humira)
- Johnson & Johnson (Remicade)
- Biosimilars from Samsung Bioepis, Celltrion, and others introduced since 2016.
Price Trends and Projections
Historical Price Data:
| Year |
Brand Price (per infusion) |
Average Biosimilar Price (per infusion) |
| 2018 |
$2,300 |
$1,800 |
| 2020 |
$2,400 |
$1,600 |
| 2022 |
$2,500 |
$1,400 |
Prices have declined due to biosimilar competition, reductions in manufacturing costs, and payer negotiations.
Price Projection (2023-2028):
| Year |
Estimated Brand Price |
Estimated Biosimilar Price |
Key Drivers |
| 2023 |
$2,500 |
$1,400 |
Market saturation, price competition |
| 2024 |
$2,450 |
$1,300 |
Patent expiries, cost efficiencies |
| 2025 |
$2,400 |
$1,200 |
Biosimilar penetration, regulatory pressures |
| 2026 |
$2,350 |
$1,100 |
Increased biosimilar approvals and uptake |
| 2027 |
$2,300 |
$1,000 |
Dominance of biosimilar options |
| 2028 |
$2,250 |
$900 |
Standardization of biosimilar pricing |
Future Influences:
- FDA and EMA biosimilar approvals will accelerate price reductions.
- Payer policies favor biosimilars, reducing reimbursement for originator biologics.
- Manufacturing advances will lower production costs, further decreasing prices.
- Patent litigation and exclusivity periods impact biosimilar entry timing.
Market Entry and Pricing Strategies:
- Payers and providers shift towards biosimilars for cost containment.
- Brand manufacturers implement pricing strategies to maintain market share, including discounts, rebates, and patient assistance programs.
- New indications and formulations could sustain higher prices for certain products.
Risks and Opportunities:
- Policy reform and biosimilar acceptance could accelerate price declines.
- Potential patent litigation delays biosimilar entry.
- Emerging markets may present higher growth opportunities with less price pressure.
- Innovation, such as new indications or combination therapies, could stabilize revenue.
Summary
NDC 35573-0443, representing infliximab from Pfizer, faces a dynamic market shaped by biosimilar competition and patent expiries. Its market share is increasingly challenged by lower-priced biosimilars, leading to a conservative price outlook over the next five years. Continued patent litigations and regulatory approvals will influence timing and extent of price erosions.
Key Takeaways:
- The infliximab market is expected to decline in reference pricing due to biosimilars.
- Prices for biosimilars could drop by approximately 35-50% by 2028.
- Market size remains substantial, but growth shifts toward biosimilar adoption.
- Companies will need strategic pricing and market access plans to sustain revenue.
- Policy landscape heavily influences future pricing and market share.
FAQs
Q1: How does biosimilar competition affect the price of NDC 35573-0443?
Biosimilars typically reduce biologic prices by 30-50%, depending on market penetration and payer negotiations.
Q2: What is the timeline for biosimilar entry for infliximab?
Biosimilar infliximab products have been available since 2016. Additional biosimilars are anticipated to enter the market as patents expire and approvals are secured.
Q3: How does patent expiration influence future revenue?
Patent expiration enables biosimilar manufacturers to launch competition, pressuring prices downward and reducing revenue for originator biologics.
Q4: Which regions offer the highest growth potential?
Emerging markets such as China, India, and Brazil present higher growth potential due to expanding healthcare infrastructure and increasing disease prevalence.
Q5: What factors could stabilize infliximab prices in the coming years?
Clinical exclusivities, new indications, or proprietary formulations could mitigate price declines temporarily.
References
- EvaluatePharma. (2022). Global biologic market forecast.
- IQVIA. (2023). Global autoimmune biologic sales data.
- MarketsandMarkets. (2022). Biosimilar market analysis.
